Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Sharp Increase In Type 2 Diabetes Boon To Drug Makers

This article was originally published in PharmAsia News

Executive Summary

Makers of drugs for diabetics report a 17 percent increase in sales in the 12-month period ending in August. Diabetic drugs also have increased from 4.6 percent of the drug market in India to 5.1 percent, according to ORG IMS. The increase, according to authorities, is due to the fact India has the world's largest population of diabetics, particularly Type 2 diabetes, which is expected to afflict more than 60 million people by 2017, up from 28 million last year. The numbers have led to an increasing number of drug makers entering that sector of the market, with GlaxoSmithKline expected to launch the first molecule for treatment within two years. (Click here for more

You may also be interested in...



India Faces Diabetes "Tsunami," Conference Told

Commercial Partner Sought For Nasal Spray Claimed To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Russia Prepares $10 COVID-19 Vaccine For International Launch

Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel